FDA Approves New Oral Combination Treatment for Common Breast Cancer Mutation
In a significant advancement for breast cancer care, the U.S. Food and Drug Administration (FDA) has approved a new oral combination therapy for patients with a specific mutation associated with advanced breast cancer. The approval, granted on September 18, allows the use of two medications—Inluriyo (imlunestrant) and Verzenio (abemaciclib)—together for adults diagnosed with estrogen receptor-positive…
